Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research report issued to clients and investors on Friday, MarketBeat Ratings reports. They currently have a $56.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $60.00. Leerink Partners’ price target would indicate a potential upside of 22.78% from the stock’s current price.
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. The Goldman Sachs Group increased their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 4th. Royal Bank of Canada restated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. Finally, StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $52.50.
Read Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Stock Performance
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.51) EPS. As a group, analysts forecast that Agios Pharmaceuticals will post -4.85 earnings per share for the current year.
Insider Activity
In related news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 4.93% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $40,000. North Star Asset Management Inc. acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $216,000. XTX Topco Ltd purchased a new stake in Agios Pharmaceuticals during the second quarter worth about $230,000. Finally, Northcape Wealth Management LLC acquired a new position in Agios Pharmaceuticals during the second quarter worth about $244,000.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Further Reading
- Five stocks we like better than Agios Pharmaceuticals
- What is the Hang Seng index?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 9/23 – 9/27
- Profitably Trade Stocks at 52-Week Highs
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.